A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems

被引:9
作者
Andonova, Velichka Yordanova [1 ]
机构
[1] Med Univ Plovdiv, Dept Pharmaceut Sci, Fac Pharm, Plovdiv 4002, Bulgaria
关键词
Ocular absorption; ocular drug delivery; nanoparticles; proniosomes; micro-needles; SOLID LIPID NANOPARTICLES; LOADED PLGA NANOPARTICLES; OCULAR DELIVERY; IN-VITRO; POSTERIOR SEGMENT; GELLING SYSTEM; CHITOSAN; TOLERABILITY; EYE; LIPOSOMES;
D O I
10.2174/1381612822666160813234723
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of each dosage form is to provide an optimal therapeutic effect with a minimum dose and with minimal side effects. This is particularly relevant for drugs that require systemic administration, higher dosing and/or show lower bioavailability. The eye as an anatomical structure is an extremely protected organ. In this regard, providing an optimal bioavailability in the eye tissues, resulting in the desired therapeutic effect represents a major challenge. This is especially true for the treatment of diseases, affecting the posterior segment after topically administered drug formulations. The use of nano-and microcarriers of drug substances may be an appropriate technological approach, to provide a high bioavailability of the drug substance for a certain interval of time at the right place. The purpose of this review is to indicate how nano-and microcarriers of drug substances can solve the problems with the drug delivery in the ocular tissues, to indicate the possible hazards and side effects, depending on the polymer nature and route of administration, and to visualize the future potential of these carriers in the pharmaceutical practice.
引用
收藏
页码:6313 / 6329
页数:17
相关论文
共 199 条
[151]  
Patel Ashaben, 2013, World J Pharmacol, V2, P47
[152]  
Patel P., 2010, Sys. Rev. Pharm, V1, P113, DOI DOI 10.4103/0975-8453.75042
[153]  
Pignatello R., 2007, Current Drug Delivery, V4, P109, DOI 10.2174/156720107780362348
[154]   Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene [J].
Pignatello, R ;
Ricupero, N ;
Bucolo, C ;
Maugeri, F ;
Maltese, A ;
Puglisi, G .
AAPS PHARMSCITECH, 2006, 7 (01)
[155]   Ocular tolerability of Eudragit RS100® and RL1009® nanosuspensions as carriers for ophthalmic controlled drug delivery [J].
Pignatello, R ;
Bucolo, C ;
Puglisi, G .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (12) :2636-2641
[156]  
Poland C. A., 2009, NANOTOXICITY VIVO IN, P61
[157]   Toxicity of nanomaterials to the eye [J].
Prow, Tarl W. .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2010, 2 (04) :317-333
[158]   Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium [J].
Prow, Tarl W. ;
Bhutto, Imran ;
Kim, Sahng Y. ;
Grebe, Rhonda ;
Merges, Carol ;
McLeod, D. Scott ;
Uno, Koichi ;
Mennon, Mohamed ;
Rodriguez, Li ;
Leong, Kam ;
Lutty, Gerard A. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2008, 4 (04) :340-349
[159]   Effect of three different liposomal eye sprays on ocular comfort and tear film [J].
Pult, Heiko ;
Gill, Felicity ;
Riede-Pult, Britta H. .
CONTACT LENS & ANTERIOR EYE, 2012, 35 (05) :203-207
[160]  
Qiu Y, 2003, Patent, Patent No. 60487780